drugset / Trial / NCT07119996
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
When bladder cancer patients are treated to mobilize their own immune system to fight the tumor, drugs that kill the bacteria can impair the effectiveness of the treatment. The purpose of this study is to find out if the common dietary supplement Vitamin B3 could allow drugs that kill bacteria to not negatively affect treatments that mobilize the immune system to fight tumors.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2026-02-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niacin | Small molecule | 300 mg | Oral |
| Subject | Niacin | Small molecule | 500 mg | Oral |
| Background | Cisplatin | Other / unclassified | 70 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | — |